Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas

In Vivo

Volumn 19, Issue 2, 2005, Pages 439-454

  Bai, Maria ^a   Papoudou Bai, Alexandra ^a   Kitsoulis, Panagiotis ^a   Horianopoulos, Nikolaos ^a   Kamina, Sevasti ^a   Agnantis, Niki John ^a   Kanavaros, Panagiotis ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apoptosis; Cell cycle; Classical Hodgkin lymphomas; Review

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLIN E; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; PROTEIN BCL XL; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; B CELL LYMPHOMA; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; REED STERNBERG CELL; REVIEW; T LYMPHOCYTE;

EID: 16344384883     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (179)

1. Harris NL: Hodgkin's disease: classification and differential diagnosis. Mod Pathol 12: 159-175, 1999.
2. Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, Pileri A Jr, Giunti M, Falini B, Bolis GB and Stein H: Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 55: 162-76, 2002.
3. Kuppers R: Molecular biology of Hodgkin's lymphoma. Adv Cancer Res 84: 277-312, 2002.
4. Kuppers R, Klein U, Schwering I, Distler V, Brauninger A, Cattoretti G, Tu Y, Stolovitzky GA, Califano A, Hansmann ML and Dalla-Favera R: Identification of Hodgkin Reed-Sternberg cell specific genes by gene expression profiling. J Clin Invest 111: 529-537, 2003.
5. Staudt LM: The molecular and cellular origins of Hodgkin's disease. J Exp Med 191: 207-212, 2000.
6. Thomas RK, Re D, Wolf J and Diehl V: Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 5: 11-18, 2004.
7. Erdkamp FL, Schouten HC, Breed WP, Janssen WC, Hoffmann JJ, Schutte B and Blijham GH: DNA aneuploidy in Hodgkin's disease: a multiparameter flow cytometric analysis. Leuk Lymphoma 12: 297-306, 1994.
8. Leoncini L, Spina D, Close P, Megha T, Pacenti L, Tosi P, Pileri S, De Vivo A, Kraft R, Laissue JA and Cottier H: Abortive mitoses and nuclear DNA fragmentation in CD30+ large cells of Hodgkin's disease. Leuk Lymphoma 22: 119-124, 1995.
9. Leoncini L, Spina D, Close P, Minacci C, Megha T, De Luca F, Tosi P, Pileri S, Kraft R, Laissue JA and Cottier H: Mitotic activity and nuclear DNA damage of large cells in Hodgkin's disease: comparison with the expression of p53 and bcl-2 proteins and the presence of Epstein-Barr virus. Leuk Lymphoma 25: 153-161, 1997.
10. Spina D, Leoncini L, Close P, Megha T, Pacenti L, Tosi P, Pileri S, Sabattini E, Kraft R, Laissue J and Cottier H: Growth vs DNA strand breaks in Hodgkin's disease: impaired proliferative ability of Hodgkin and Reed-Sternberg cells. Int J Cancer 66: 179-183, 1996.
11. Leoncini L, Spina D, Megha T, Gallorini M, Tosi P, Hummel M, Stein H, Pileri S, Kraft R, Laissue JA and Cottier H: Cell kinetics, morphology, and molecular IgVH gene rearrangements in Hodgkin's disease. Leuk Lymphoma 26: 307-316, 1997.
12. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnld W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dorken B: Constitutive nuclear factor-kappaB-ReIA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100: 2961-2969, 1997.
13. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B and Scheidereit C: Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86 and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 97: 2798-2807, 2001.
14. Izban KF, Ergin M, Huang Q, Qin Jz, Martinez RL, Schnitzer B, Ni H, Nickoloff BJ and Alkan S: Characterization of nf-kappab expression in Hodgkin's disease: inhibition of constitutively expressed nf-kappab results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol 14: 297-310, 2001.
15. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S, Dorken B, Zenke M, Stein H and Scheidereit C: Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196 605-617, 2002
16. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dorken B and Scheidereit C: Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21: 4104-4113, 2002.
17. Lauritzen AF, Moller PH, Nedergaard T, Guldberg P, Hou-Jensen K and Ralfkiaer E: Apoptosis related genes and proteins in Hodgkin's disease. APMIS 107: 636-644, 1999.
18. Sanchez-Beato M, Piris MA, Martinez-Montero JC, Garcia JF, Villuendas R, Garcia FJ, Orradre JL and Martinez P: Mdm2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Reed-Sternberg cells in Hodgkin's disease. J Pathol 180: 58-64, 1996.
19. Tzardi M, Kouvidou C, Panagiotides I, Stefanaki K, Giannikaki E, Zois E, Koutsoubi K, Darivianaki K, Karidi E, Delides G and Kanavaros P: Expression of p53 and mdm2 proteins in Hodgkin's disease. Absence of correlation with the presence of Epstein-Barr Virus. Anticancer Res 16 2813-2820, 1996.
20. Kupper M, Joos S, Von Bonin F, Daus H, Pfreundschuh M, Lichter P and Trumper L: MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 112: 768-775, 2001.
21. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, Fraga M, Garcia-DelMoral R, Gomez-Marcos F, Menarguez J, Oliva H, Sanchez-Beato M and Montalban C: Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index and absence of Epstein-Barr virus Latent Membrane Protein 1 expression. Blood 80: 2429-2436, 1997.
22. Montesinos-Rongen M, Roers A, Kuppers R, Rajewsky K and Hansmann ML: Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 94: 1755-1760, 1999.
23. Brink AA, Oudejans JJ, van den Brule AJ, Kluin PM, Horstman A, Ossenkoppele GJ, van Heerde P, Jiwa M and Meijer C: Low p53 and high bc12 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement in apoptosis resistance. Mod Pathol 11: 376-383, 1998.
24. Garcia JF, Villuendas R, Algara P, Saez AI, Sanchez-Verde L, Martinez-Montero JC, Martinez P and Piris MA: Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab Invest 79: 1453-1459, 1999.
25. Guenova M, Rassidakis GZ, Gorgoulis VG, Angelopoulos MK, Siakantaris MR, Kanavaros P, Pangalis GA and Kittas C: p16/INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr Virus. Mod Pathol 12: 1062-1071; 1999.
26. Ohshima K, Haraoka S, Fujiki T, Yoshioka S, Suzumiya J and Kand M: Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: not suppressed by cyclin-dependent kinase inhibitor p21 expression. Pathol Int 49: 506-512, 1999.
27. Bai M, Tsanou E, Agnantis NJ, Kamina S, Grepi C, Stefanaki K, Rontogianni D, Galani V and Kanavaros P: Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin and Reed-Sternberg cells. Mod Pathol 17: 1338-1345, 2004.
28. Kanavaros P, Stefanaki K, Vlachonikolis J, Eliopoulos G, Kakolyris S, Rontogianni D, Gorgoulis V and Georgoulias V: Expression of p53, p21/waf-1, bcl-2, bax, Rb and Ki-67 proteins in Hodgkin's lymphomas. Histol Histopathol 15: 445-453, 2000.
29. Kolar Z, Flavell JR, Ehrman J, Rihakova P, Macak J, Lowe D, Crocker J, Vojtesek B, Young LS and Murray PG: Apoptosis in malignant cells in Hodgkin's disase is related to expression of the cdk inhibitor p27KIP1. J Pathol 190: 604-612, 2000.
30. Garcia JF, Villuendas R, Sanchez-Beato M, Sanchez-Aguilera A, Sanchez L, Prieto I and Piris MA: Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts. Am J Pathol 160: 569-578, 2002.
31. Garcia MJ, Martinez-Delgado B, Cebrian A, Martinez A, Benitez J and Rivas C: Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am I Pathol 161: 1007-1013, 2002.
32. Sanchez-Aguilera A, Delgado J, Camacho FI, Sanchez-Beato M, Sanchez L, Montalban C, Fresno MF, Martin C, Piris MA and Garcia JF: Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 103: 2351-2357, 2004.
33. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, Bellas C, Castano A, Diez A, Flores T, Martin C, Martinez MA, Mazorra F, Menarguez J, Mestre MJ, Mollejo M, Saez AI, Sanchez L and Piris MA: Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 101: 681-689, 2003.
34. Teramoto N, Pokrovskaja K, Szekely L, Polack A, Yoshino T, Akagi T and Klein G: Expression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer 81: 543-550, 1999.
35. Tzankov A, Zimpfer A, Lugli A, Krugmann J, Went P, Schraml P, Maurer R, Ascani S, Pileri S, Geley S and Dirnhofer S: High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J Pathol 199 201-207, 2003.
36. Skinnider BF, Kapp U and Mak TW: The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 43: 1203-1210, 2002.
37. Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000.
38. Malumbres M and Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231, 2001.
39. Igney FH and Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288, 2002.
40. Rossi D and Gaidano G: Messengers of cell death: apoptotic signaling in health and disease. Haematologica 88: 212-218, 2003.
41. Vermeulen K, Berneman ZW and van Bockstaele DR: Cell cycle and apoptosis. Cell Prolif 36: 165-175, 2003.
42. Opferman JT and Korsmeyer SJ: Apoptosis in the development and maintenance of the immune system. Nat Immunol 4: 410-415, 2003.
43. Sanchez-Beato M, Sanchez-Aguilera A and Piris MA: Cell cycle deregulation in B-cell lymphomas. Blood 101: 1220-35, 2003.
44. Leoncini L, Lazzi S, Bellan C and Tosi P: Cell kinetics and cell cycle regulation in lymphomas. J Clin Pathol 55: 648-655, 2002.
45. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farihna P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO and Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-82, 2003.
46. Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat AM, Marie JP and Zittoun R: Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85: 2870-2876, 1995.
47. Bai M, Tsanou E, Agnantis NJ, Dimou D, Chaidos A, Skyrlas A, Dimou S, Vlychou M, Galani V and Kanavaros P: Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferative activity and apoptosis status in diffuse large B-cell lymphomas. Histol Histopathol 18: 449-457, 2003.
48. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C and Pirker R: Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 8: 729-733, 2002.
49. Doglioni C, Chiarelli C, Macri E, Dei Tos AP, Meggiolaro E, Dalla Palma P and Barbareschi M: Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol 185: 159-166, 1998.
50. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G and Landberg G: Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 92 770-777, 1998.
51. Spruck CH, Won KA and Reed SI: Deregulated cyclin E induces chromosome instability. Nature 401: 297-300, 1999.
52. D'Angiolella V, Costanzo V, Gottesman ME, Avvedimento EV, Gautier J and Grieco D: Role for cyclin-dependent Kinase 2 in mitosis exit. Curr Biol 11: 1221-26, 2001.
53. Bai M, Vlachonikolis J, Agnantis NJ, Tsanou E, Dimou S, Nicolaides C, Stefanaki S, Pavlidis N and Kanavaros P: Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. Mod Pathol 14: 1105-1113, 2001.
54. Den Eltzen N and Pines J: Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase. J Cell Biol 153: 121-136, 2001.
55. Smits V and Medema R: Checking out the G2/M transition. Biochemica et Biophysica Acta 1519: 1-12, 2001.
56. Leoncini L, Megha T, Lazzi S, Bellan C, Luzi P, Tosi P, Cevenini G, Barbini P, Ascani S, Briskomatis A, Pileri S, Kraft R, Laissue JA and Cottier H: Cellular kinetic differences between Hodgkin's disease and anaplastic large cell lymphomas: relation to the expression of p34cdc2 and cyclins B1. Int J Cancer 29: 408-414, 1998.
57. Bellan C, De Falco G, Lazzi S, Micheli P, Vicidomini S, Schurfeld S, Amato T, Palumbo A, Bagella L, Sabattini E, Bartolomei S, Hummel M, Pileri S, Tosi P, Leoncini L and Giordano A: CDK9/Cyclin T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol 203: 946-952, 2004.
58. Blais A, Monte D, Pouliot F and Labrie C: Regulation of the human cyclin-dependent kinase inhibitor p181NKc by the transcription factors E2F1 and Sp1. J Biol Chem 277: 31679-31693, 2002.
59. Tourigny MR, Ursini-Siegel J and Lee H: CDK inhibitor p18(INKc) is required for the generation of functional plasma cells. Immunity 17: 179-189, 2002.
60. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I, Lammert H, Demel G, Theil J, Wirth T and Stein H: Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrengements but defective immunoglobulin transcription. Blood 95: 1443-1450, 2000.
61. Stein H, Marafioti T, Foss HD, Laumen H, Hummel M, Anagnostopoulos I, Wirth T, Demel G and Falini B: Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin's disease but not in lymphocyte predominant Hodgkin's disease correlates with immunoglobulin transcription. Blood 97: 496-501, 2001.
62. Jundt F, Kley K, Anagnostopoulos I, Schulze-Probsting K, Greiner A, Mathas S, Scheidereit C, Wirth T, Stein H and Dorken B: Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 99: 3060-3062, 2002.
63. Taylor WR, Deprimo SE, Agarwal A, Agarwal ML, Schonthal AH, Katula KS and Stark GR: Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell 10: 3607-3622, 1999.
64. Innocente SA, Abrahamson JLA, Cogswell JP and Lee JM: P53 regulates a G2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 96 2147-2152, 1999.
65. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, Garcia JF and Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression and p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 94: 765-772, 1999.
66. Moller MB: P27 in cell cycle control and cancer. Leuk Lymphoma 39: 19-27, 2000.
67. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC and Scheithauer BW: P27/KIP1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154: 313-323, 1998.
68. Sanchez-Beato M, Saez AI, Martinez-Montero JC, Sol-Mateo M, Sanchez-Verde L, Villuendas R, Troncone G and Piris MA: Cyclin-dependent kinase inhibitor p27/KIP1 in lymphoid tissue. P27/KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 151: 151-160, 1997.
69. Karin M, Cao Y, Greten FR and Li ZW: NF-kB in cancer. From innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
70. Karin M and Lin A: NF-kappa B at the crossroads of life and death. Nat Immunol 3: 221-227, 2002.
71. Younes A, Garg A and Aggarwal BB: Nuclear transcription factor-kappa B in Hodgkin's disease. Leuk Lymphoma 44: 929-935, 2003.
72. Bargou RC, Leng C, Krappmann D, Bommert K, Mapara MY, Arnld W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dorken B: High level nuclear F-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed Sternberg cells. Blood 87: 4340-4347, 1996.
73. Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Krappmann D, Scheidereit C, Stein H and Dörken B: Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94: 3129-3134, 1999.
74. Oshima K, Sugihara M, Haraoka S, Suzumiya J, Kanda M, Kawasaki C, Shimazaki K and Kikuchi M: Possible immortalization of Hodgkin and Reed-Sternberg cells: telomerase expression, lengthening of telomere and inhibition of apoptosis by NF-kappa B expression. Leuk Lymphoma 41: 367-376, 2001.
75. Jungnickel B, Staratschek-Jox A, Bräuninger A, Spieker T, Wolf J, Diehl V, Hansmann ML, Rajewsky K and Kuppers R: Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 191: 395-402, 2000.
76. Joos S, Kupper M, Ohl S, von Bonin F, Mechtersheimer G, Bentz M, Marynen P, Moller P, Pfreudschuh M, Trumper L and Lichter P: Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 60: 549-552, 2000.
77. Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S, Mechtersheimer G, Trümper L, Möller P, Lichter P and Barth TFE: Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 99: 1381-1387, 2002.
78. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML, Dyer JS and Siebert R: Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99: 1474-1477, 2002.
79. Annunziata CM, Safiran YJ, Irving SG, Kasid UN and Cossman J: Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. Blood 96: 2841-2848, 2000.
80. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F, Aggarwal BB and Younes A: Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 98: 2784-2790, 2001.
81. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, Saito I, Higashihara M, Mori S, Kadin ME and Watanabe T: Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21: 2493-503, 2002.
82. Gruss HJ, Herrmann F, Gattei V, Gloghini A, Pinto A and Carbone A: CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 24: 393-422, 1997.
83. Mir SS, Richter BW and Duckett CS: Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 98: 1630-2, 2001.
84. Gruss HJ, Pinto A, Gloghini A, Welmes E, Wright B, Boiani N, Aldinucci D, Gattei V, Zagonel V, Smith CA, Kadin ME, von Schilling C, Goodwin RG, Herrmann F and Carbone A: CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 149: 469-81, 1996.
85. Schlaifer D, Krajewski S, Rigal-Huguet F, Laurent G, Pris J, Delsol G, Reed JC and Brousset P: Bcl-x gene expression in Hodgkin's disease. Leuk Lymphoma 23: 143-146, 1996.
86. Lorenzen J, Thile J and Fischer R: The mummified Hodgkin cell: cell death in Hodgkin's disease. J Pathol 182: 288-298, 1997.
87. Messineo C, Hunter-Jamerson M, Hunter E, Braziel R, Bagg A, Irving SG and Cossman J: Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood 91: 2443-2451, 1998.
88. Chu WS, Aguilera NS, Wei MQ and Abbondanzo SL: Antiapoptotic marker Bcl-X (L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Hum Pathol 30: 1065-1070, 1999.
89. Kim LH, Nadarajah VS, Peh SC and Poppema S: Expression of bc12 family members and presence of Epstein-Barr virus in the regulation of cell growth and death in classical Hodgkin's lymphoma. Histopathology 44: 257-267, 2004.
90. Arch RH, Gedrich RW and Thompson CB: Tumor necrosis factor receptor-associated factors (TRAFs)- a family of adapter proteins that regulates life and death. Genes Dev 12: 2821-2830, 1998.
91. Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S and Yamamoto T: Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 254: 14-24, 2000.
92. Horie R, Watanabe T, Ito K, Morisita Y, Watanabe M, Ishida T, Higashihara M, Kadin M and Watanabe T: Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol 160: 1647-54, 2002.
93. Durkop H, Hirsch B, Hahn C, Foss HD and Stein H: Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. J Pathol 200: 229-239, 2003.
94. Izban KF, Ergin M, Martinez RL and Alkan S: Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells. Mod Pathol 13: 1324-1331, 2000.
95. Durkop H, Foss HD, Demel G, Klotzbach H, Hahn C and Stein H: Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood 93: 617-623, 1999.
96. Murray PG, Flavell JR, Baumforth KR, Toomey SM, Lowe D, Crocker J, Ambinder RF and Young LS: Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin's disease. J Pathol 194: 158-164, 2001.
97. Thomas RK, Kallenborn A, Wickenhauser C, Schultze JL, Draube A, Vockerodt M, Re D, Diehl V and Wolf J: Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol 160: 1521-1528. 2002.
98. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M, Jundt F, Hirsch B, Johrens-Leder K, Vornlocher HP, Bommert K, Stein H and Dorken B: C-FLIP mediates resistance of Hodgkin and Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199: 1041-1052, 2004.
99. Dukers DF, Meijer C, ten Berge RS, Vos W, Ossenkoppele GJ and Oudejans J: High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin's disease predict favorable clinical outcome. Blood 100: 36-42, 2002.
100. Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M and Jurgensmeier JM: XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B-cells. J Exp Med 198: 341-347, 2003.
101. Mushen M, Re D, Brauninger A, Wolf J, Hansmann ML, Diehl V, Kruppers R and Rajewsky K: Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res 60: 5640-5643, 2000.
102. Maggio EM, Van der Berg A, de Jong D, Diepstra A and Poppema S: Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. Am J Pathol 162: 29-35, 2003.
103. Metkar SS, Naresh KN, Redkar AA, Soman CS, Advani SH and Nadkarni JJ: Expression of Fas and Fas ligand in Hodgkin's disease. Leuk Lymphoma 33: 521-530, 1999.
104. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
105. Ihle JN: The Star family in cytokine signalling. Curr Opin Cell Biol 13: 211-217, 2001.
106. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B Behrmann I, Heinrich PC, Diehl V and Tesch H: STAT3 is constitutively activated in Hodgkin cell lines. Blood 98: 762-770, 2001.
107. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U and Mak TW: Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99: 618-626, 2002.
108. Skinnider BF and Mak TW: The role of cytokines in classical Hodgkin lymphoma. Blood 99: 4283-4297, 2002.
109. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, Hessel A, Tipsword M, Williams A, Mirtsos C, Itie A, Moyle M and Mak TW: Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189: 1939-46, 1999.
110. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K and Kikuchi M: Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 38: 368-75, 2001.
111. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, Patterson B, Snow BE and Mak TW: Interleukin-13 and interleukin-13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97: 250-255, 2001.
112. Lomo J, Blomhoff HK, Jacobsen SE, Krajewski S, Reed JC and Smeland EB: Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1. Blood 89: 4415-4424, 1997.
113. Karin M, Liu ZG and Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997.
114. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001.
115. Teofili L, Febo AL, Pierconti F, Magiano N, Bernadini M, Rutella S, Cingolani A, Renzo ND, Musto P, Pileri S, Leone G and Larocca LM: Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 97: 1063-1069, 2001.
116. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A and Younes A: MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40 and RANK that regulates cell proliferation and survival. Blood 102: 1019-1027, 2003.
117. Kuppers R: B cells under influence: transformation of B-cells by Epstein-Barr virus. Nat Rev Immunol 3: 801-812, 2003.
118. Thorley-Lawson DA: Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1: 75-82, 2001.
119. Baumforth KR, Young LS, Flavell KJ, Constantinou C and Murray PG: The Epstein-Barr virus and its association with human cancers. J Clin Pathol Mol Pathol 52: 307-322, 1999.
120. Young LS, Dawson CW and Eliopoulos AG: The expression and function of Epstein-Barr virus encoded latent genes. J Clin Pathol Mol Pathol 53: 238-247, 2000.
121. Flavell KJ and Murray PG: Hodgkin's disease and the Epstein-Barr virus. J Clin Pathol Mol Pathol 53: 262-269, 2000.
122. Portis T, Dyck P and Longnecker R: Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102: 4166-4178, 2003.
123. Sinclair AJ, Fenton M and Delikat S: Interactions between Epstein-Barr virus and the cell cycle control machinery. Histol Histopathol 13: 461-467, 1998.
124. Brennan P: Signalling events regulating lymphoid growth and survival. Sem Cancer Biol 11: 415-421, 2001.
125. Niedobitek G, Kremmer F, Herbst H, Whitehead L, Dawson CW, Niedobitek E, von Ostau C, Rooney N, Grasser FA and Young LS: Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 90: 1664-1672, 1997.
126. Herbst H, Stein H and Niedobitek G: Epstein-Barr virus and CD30 positive malignant lymphomas. Crit Rev Oncogen 4: 191-239, 1993.
127. Weiss LM, Strickler JG, Warnke RA, Purtilo DT and Sklar J: Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 129: 86-91, 1987.
128. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Lisse I, Ralfkiaer E, Sandvej K and Young LS: Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337: 320-322, 1991.
129. Karameris A and Kanavaros P: Demonstration of Epstein-Barr virus genome in neoplastic cells of Hodgkin's disease by in situ hybridization in paraffin sections using biotinylated probes. A study of 46 cases. Pathology Res Pract 188: 311-313, 1992.
130. Kanavaros P, Jiwa M, DeBruin P, van der Valk P, Horsman A, Vos W, Mullink H, Walboomers JMM and Meijer CJLM: High incidence of EBV genome in CD30 positive non-Hodgkin's lymphomas. J Pathol 168: 307-315, 1992.
131. Jiwa NM, Kanavaros P, de Bruin P, van der Valk P, Horsman A, Vos W, Mullink H, Walboomers JMM and Meijer CJLM: Presence of Epstein-Barr virus harbouring small and intermediate sized cells in Hodgkin's disease. Is there a relationship with Reed-Sternberg cells? J Pathol 170: 129-136, 1993.
132. Jiwa M, Kanavaros P, Van Der Valk P, Walboomers J, Horstman A, Vos W and Meijer C: Reed-Sternberg cells in Hodgkin's disease express frequently c-myc and bcl-2 oncogene products independently of the presense of EBV. J Clin Pathol 46: 211-217, 1993.
133. Kanavaros P, Jiwa M, Van Der Valk P, Walboomers J, Horstman A and Meijer C: Expression of EBV latent gene products and associated activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in non-immunocompromised individuals. Hum Pathol 24 725-729, 1993.
134. Kanavaros P, Sakalidou A, Tzardi M, Delidis G, Kazlaris E and Kalmanti M: Frequent detection of EBV-encoded EBER transcripts and LMP-1 protein in tumour cells in Hodgkin's disease arising in childhood. Pathology Res Pract 190: 1026-1030, 1994.
135. Bai MC, Jiwa NM, Horstman A, Vos W, Kluin PH, Van der Valk P, Mullink H, Walboomers JM and Meijer CJ: Decreased expression of cellular markers in Epstein-Barr virus-positive Hodgkin's disease. J Pathol 174 49-55, 1994.
136. Jiwa NM, Oudejans JJ, Bai MC, Van den Brule AJ, Horstman A, Vos W, Van der Valk P, Kluin PM, Walboomers JM and Meijer CJ: Expression of bcl-2 protein and transcription of the Epstein-Barr virus bcl-2 homologue BHRF-1 in Hodgkin's disease: implications for different pathogenic mechanisms. Histopathology 26: 547-53, 1995.
137. Panayiotides J, Kanavaros P, Protopapa E, Vlachonikolis J, Tzardi M, Kalmanti M and Delidis G: Morphological differences between LMP-1 positive and negative tumor cells in EBV-related childhood Hodgkin's disease. A morphometric study. Pathology Res Pract 192: 1-10, 1996.
138. Tzardi M, Kouvidou C, Papakonstantinou E, Datseris G, Darivianaki K, Karidi E, Eliopoulos G, Rontogianni D and Kanavaros P: MHC-I and MHC-II expression in Hodgkin's disease in relation to the presence of Epstein-Barr virus. Anticancer Res 16: 827-832, 1996.
139. Sandvej K, Andresen BS, Zhou XG, Gregersen N and Hamilton-Dutoit S: Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site. J Clin Pathol Mol Pathol 53: 280-288, 2000.
140. Garcia-Cosio M, Santon A, Marin P, Camarasa N, Montalban C, Garcia JF and Bellas C: Analysis of transcrition factors Oct1, Oct2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma. Mod Pathol Jul 16, 2004 [Epub ahead of print].
141. Preciado MV, Cristobal E, Menarguez J, Martinez Montero JC, Diez B, De Matteo E and Grinstein S: Oncogene expression in tumour cells of pediatric Hodgkin's disease in Argentina-correlation with Epstein Barr virus presence. Pathol Res Pract 194: 25-31, 1998.
142. Siegler G, Kremmer E, Gonnella R and Niedobitek G: Epstein Barr virus-encoded latent membrane protein 1 (LMP1) and TNF receptor associated factors: colocalisation of LMP1 and TRAF1 in primary EBV infection and in EBV associated Hodgkin lymphoma. J Clin Pathol Mol Pathol 56: 156-161, 2003.
143. Vassalo J, Metze K, Traina F, de Souza CA and Lorand-Metze I: The prognostic relevance of apoptosis-related proteins in classical Hodgkin's lymphomas. Leuk Lymphoma 44: 483-488, 2003.
144. Smolewski P, Niewiadomska H, Los E and Robak T: Spontaneous apoptosis of Reed-Sternberg and Hodgkin's cells; clinical and pathological implications in patients with Hodgkin's disease. Int J Oncol 17: 603-609, 2000.
145. Murray PG, Billingham LJ, Hassan HT, Flavell JR, Nelson PN, Scott K, Reynolds G, Constandinou CM, Kerr DJ, Devey EC, Crocker J and Young LS: Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood 94: 442-447, 1999.
146. Kim SH, Shin YK, Lee IS, Bae YM, Sohn HW, Suh YH, Ree HJ, Rowe M and Park SH: Viral latent membrane protein 1 (LMP-1)-induced CD99
147. Lee IS, Shin YK, Chung DH and Park SH: LMP1-induced down-regulation of CD99 molecules in Hodgkin and Reed-Sternberg cells. Leuk Lymphoma 42: 587-594, 2001.
148. Krueger GR, Huetter ML, Rojo J, Romero M and Cruz-Ortiz H: Human herpes viruses HHV-4 (EBV) and HHV-6 in Hodgkin's and Kikuchi's diseases and their relation to proliferation and apoptosis. Anticancer Res 21: 2155-2166, 2001.
149. Montalban C, Abraira V, Morente M, Acevedo A, Aguilera B, Bellas C, Fraga M, Del Moral RG, Menarguez J, Oliva H, Sanchez-Beato M and Piris MA: Epstein-Barr virus-latent membrane protein 1 expression has a favorable influence in the outcome of patients with Hodgkin's disease treated with chemotherapy. Leuk Lymphoma 39: 563-572, 2000.
150. Herbst H, Samol J, Foss HD, Raff T and Niedobitek G: Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol 182: 299-306, 1997.
151. Dukers DF, Jaspars LA, Vos W, Oudejans JJ, Hayes D and Gillessen S: Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and-negative cases of Hodgkin's disease. J Pathol 190: 143-149, 2000.
152. Spender LC, Cornish GH, Rowland B, Kempkes B and Farrell PJ: Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J Virol 75: 3537-3546, 2001.
153. Beatty PR, Krams SM and Martinez OM: Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 158 4045-4051, 1997.
154. Stuart AD, Stewart JP, Arrand JR and Mackett M: The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. Oncogene 11: 1711-1719, 1995.
155. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW and Young LS: Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274: 16085-16096, 1999.
156. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M and Young LS: Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 14: 2899-2916, 1997.
157. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R and Masucci MG: The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 57: 240-244, 1994.
158. Vockerodt M, Haier B, Buttgereit P, Tesch H and Kube D: The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 280: 183-198, 2001.
159. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R and Finke J: Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88: 809-816, 1996.
160. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, Ueffing M and Hammerschmidt W: Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 18: 3064-3073, 1999.
161. Schwaller J, Tobler A, Niklaus G, Hurwitz N, Hennig I, Fey MF and Borisch B: Interleukin 12 expression in human lymphomas and non-neoplastic lymphoid disorders. Blood 85: 2182-2188, 1995.
162. Kanzler H, Kuppers R, Hansmann ML and Rajewski K: Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184: 1495-1505, 1996.
163. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, RosenwaldA, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JD, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 503-511, 2000.
164. Davis RE, Brown KD, Siebenlist U and Staudt LM: Constitutive nuclear factor KappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861-1874, 2001.
165. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R and Gaidano G: Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 117: 366-372, 2002.
166. Carbone A, Gloghini A, Gaidano G, Franceschi S, Capello D, Drexler HG, Falini B and Dalla-Favera R: Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 92: 2220-2228, 1998.
167. Dogan A, Bagdi E, Munson P and Isaacson PG: CD 10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 26: 846-852, 2000.
168. Schwering L, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, Hansmann ML, Dalla-Favera R, Rajewsky K and Kuppers R: Loss of B lineage specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin's lymphoma. Blood 101: 1504-1512, 2003.
169. Saez AI, Artiga MJ, Sanchez-Beato M, Sanchez-Verde L, Garcia JF, Camacho FI, Franco R and Piris MA: Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas. Mod Pathol 15: 211-220, 2002.
170. Tzankov A, Zimpfer A, Pebrs AC, Lugli A, Went P, Maurer R, Pileri S and Dirnhofer S: Expression of B-cell markers in classical Hodgkin's lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 16: 1141-1147, 2003.
171. Bai M, Agnantis NJ, Skyrlas A, Tsanou E, Kamina S, Galani V and Kanavaros P: Bc16 and CD10 expression is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol 16: 471-480, 2003.
172. Bai M, Skyrlas A, Agnantis NJ, Tsanou E, Kamina S, Galani V and Kanavaros P: Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the pro-apoptotic proteins bax, bak and bid and low expression of the anti-apoptotic protein bcl-xl. Mod Pathol 17: 847-856, 2004.
173. Bai M, Skyrlas A, Agnantis NJ, Kamina S, Kitsoulis P and Kanavaros P: Cluster analysis of apoptosis-associated bc12 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes. Anticancer Res 24: 3081-3088, 2004.
174. Bai M, Skyrlas A, Agnantis NJ, Kamina S, Kitsoulis P and Kanavaros P: Relations between B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas. Anticancer Res, in press.
175. Abele MC, Valente G, Kerim S, Navone R, Onesti P, Chiusa L, Resegotti L and Palestro G: Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immumohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica 82: 281-5, 1997.
176. Smolewski P, Robak T, Krykowski E, Blasinska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E and Zambrano O: Prognostic factors in Hodgkin's disease: multivariate analysis from a single institution. Clin Cancer Res 6: 1150-1160, 2000.
177. Montalban C, Garcia JF, Abraira V, Gonzalez-Camacho L, Morente MM, Bello JL, Conde E, Cruz MA, Garcia-Sanz R, Garcia-Larana J, Grande C, Llanos M, Martinez R, Flores E, Mendez M, Ponderos C, Rayon C, Sanchez-Godoy P, Zamora J and Piris MA: Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's lymphoma study group. J Clin Oncol 22: 1664-1673, 2004.
178. Devilard E, Bertucci F, Trempat P, Bouabdallah R, Loriod B, Giaconia A, Brousset P, Granjeaud S, Nguyen C, Birnbaum D, Birg F, Houlgatte R and Xerri L: Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 21: 3095-102, 2002.
179. Benharroch D, Levy A, Prinsloo I, Ariad S, Rabinovitch D, Shendler Y, Sacks M and Gopas J: Apoptotic index as a prognostic factor in Hodgkin's disease. Leuk Lymphoma 33: 351-359, 1999.